Novartis AG
NVS105.850USD
-6.400-5.70%
收盘 04/04, 16:00（美东）报价延迟15分钟
209.06B总市值
17.51市盈率 TTM
关于 Novartis AG 公司
诺华公司是一家总部位于瑞士的制药公司。该公司开发、生产和销售品牌和仿制药处方药、活性药物成分 (API)、生物仿制药和眼科产品。该公司利用科学和数字技术治疗免疫学、皮肤病学、癌症、眼科、神经科学、呼吸、心血管、肾脏和代谢等疾病领域。该公司的业务活动分为两个部门：创新药物部门，包括用于治疗血压、癌症和其他疾病的创新专利保护处方药；山德士部门，包括仿制药和生物仿制药。
公司简介
公司代码NVS
公司名称Novartis AG
上市日期May 07, 2001
成立日期1996
CEODr. Vasant (Vas) Narasimhan, M.D.
员工数量75883
证券类型Ordinary Share
年结日May 07
公司地址Lichtstrasse 35
城市BASEL
上市交易所Johannesburg Stock Exchange
国家Switzerland
邮编4056
电话41613241111
网址https://www.novartis.com/
公司代码NVS
上市日期May 07, 2001
成立日期1996
公司高管
名称
名称/职务
职务
持股
持股变动
Mr. Patrick Horber, M.D.
Mr. Patrick Horber, M.D.
President - International, Member of the Executive Committee
President - International, Member of the Executive Committee
--
--
Ms. Ana de Pro Gonzalo
Ms. Ana de Pro Gonzalo
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Ms. Elizabeth Mcnally
Ms. Elizabeth Mcnally
Director
Director
--
--
Mr. Giovanni Caforio
Mr. Giovanni Caforio
Chairman of the Board
Chairman of the Board
--
--
Mr. John D. Young
Mr. John D. Young
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Robert (Rob) Kowalski
Dr. Robert (Rob) Kowalski
Chief People and Organization Officer, Member of the Executive Committee
Chief People and Organization Officer, Member of the Executive Committee
--
--
Dr. Fiona H. Marshall, Ph.D.
Dr. Fiona H. Marshall, Ph.D.
President - Biomedical Research, Member of the Executive Committee
President - Biomedical Research, Member of the Executive Committee
--
--
Dr. Shreeram Aradhye, M.D.
Dr. Shreeram Aradhye, M.D.
President - Global Drug Development and Chief Medical Officer, Member of the Executive Committee
President - Global Drug Development and Chief Medical Officer, Member of the Executive Committee
--
--
Dr. Simon E. Moroney
Dr. Simon E. Moroney
Independent Non-Executive Vice Chairman of the Board
Independent Non-Executive Vice Chairman of the Board
--
--
Ms. Karen L. Hale
Ms. Karen L. Hale
Chief Legal Officer, Member of the Executive Committee
Chief Legal Officer, Member of the Executive Committee
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Mr. Patrick Horber, M.D.
Mr. Patrick Horber, M.D.
President - International, Member of the Executive Committee
President - International, Member of the Executive Committee
--
--
Ms. Ana de Pro Gonzalo
Ms. Ana de Pro Gonzalo
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Ms. Elizabeth Mcnally
Ms. Elizabeth Mcnally
Director
Director
--
--
Mr. Giovanni Caforio
Mr. Giovanni Caforio
Chairman of the Board
Chairman of the Board
--
--
Mr. John D. Young
Mr. John D. Young
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Robert (Rob) Kowalski
Dr. Robert (Rob) Kowalski
Chief People and Organization Officer, Member of the Executive Committee
Chief People and Organization Officer, Member of the Executive Committee
--
--
收入明细
单位: USD更新时间: 5 小时前
单位: USD更新时间: 5 小时前
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
业务USD
名称
营收
占比
Rest of portfolio
10.07B
20.02%
Cardiovascular, Renal and Metabolism - Entresto
7.82B
15.55%
Immunology - Cosentyx
6.14B
12.20%
Neuroscience - Kesimpta
3.22B
6.41%
Oncology -Kisqali
3.03B
6.03%
Other
20.02B
39.80%
地区USD
名称
营收
占比
United States
21.15B
42.03%
Other Foreign-
18.51B
36.79%
China
3.89B
7.73%
Germany
3.66B
7.27%
France
1.79B
3.56%
Switzerland
1.31B
2.61%
业务
地区
业务USD
名称
营收
占比
Rest of portfolio
10.07B
20.02%
Cardiovascular, Renal and Metabolism - Entresto
7.82B
15.55%
Immunology - Cosentyx
6.14B
12.20%
Neuroscience - Kesimpta
3.22B
6.41%
Oncology -Kisqali
3.03B
6.03%
Other
20.02B
39.80%
股东统计
更新时间: 3月28日 周五
更新时间: 3月28日 周五
持股股东
股东类型
持股股东
股东统计
占比
Dodge & Cox
0.62%
PRIMECAP Management Company
0.56%
Dimensional Fund Advisors, L.P.
0.41%
Loomis, Sayles & Company, L.P.
0.28%
Franklin Mutual Advisers, LLC
0.22%
Other
97.91%
持股股东
股东统计
占比
Dodge & Cox
0.62%
PRIMECAP Management Company
0.56%
Dimensional Fund Advisors, L.P.
0.41%
Loomis, Sayles & Company, L.P.
0.28%
Franklin Mutual Advisers, LLC
0.22%
Other
97.91%
股东类型
股东统计
占比
Investment Advisor
3.26%
Investment Advisor/Hedge Fund
2.64%
Research Firm
0.37%
Hedge Fund
0.28%
Bank and Trust
0.12%
Pension Fund
0.03%
Family Office
0.01%
Other
93.29%
机构持股
更新时间: 2月20日 周四
更新时间: 2月20日 周四
报告期
机构数
持股数
持股占比
持股变动
2025Q1
1884
133.48M
6.75%
-9.09M
2024Q4
1926
134.00M
6.78%
-9.24M
2024Q3
1858
134.89M
6.74%
-11.71M
2024Q2
1840
139.20M
6.87%
-9.16M
2024Q1
1808
141.30M
6.92%
-7.93M
2023Q4
1811
141.99M
6.94%
-15.97M
2023Q3
1775
150.92M
7.33%
-7.18M
2023Q2
1759
150.74M
7.28%
-24.15M
2023Q1
1762
167.49M
7.98%
-13.01M
2022Q4
1782
173.67M
8.19%
-17.15M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
Dodge & Cox
12.21M
0.62%
-7.21K
-0.06%
Dec 31, 2024
PRIMECAP Management Company
11.03M
0.56%
-983.02K
-8.19%
Dec 31, 2024
Dimensional Fund Advisors, L.P.
8.18M
0.41%
+90.82K
+1.12%
Dec 31, 2024
Loomis, Sayles & Company, L.P.
5.58M
0.28%
-192.68K
-3.34%
Dec 31, 2024
Franklin Mutual Advisers, LLC
4.26M
0.22%
-16.98K
-0.40%
Dec 31, 2024
Wellington Management Company, LLP
3.65M
0.18%
-351.31K
-8.78%
Dec 31, 2024
Morgan Stanley Smith Barney LLC
3.59M
0.18%
-52.88K
-1.45%
Dec 31, 2024
Parametric Portfolio Associates LLC
2.98M
0.15%
-86.17K
-2.81%
Dec 31, 2024
Managed Account Advisors LLC
2.95M
0.15%
-214.17K
-6.76%
Dec 31, 2024
Renaissance Technologies LLC
2.67M
0.14%
+368.17K
+16.00%
Dec 31, 2024
查看更多
持股ETF
更新时间: 17 小时前
更新时间: 17 小时前
机构名称
占比
VanEck Pharmaceutical ETF
5.37%
Cullen Enhanced Equity Income ETF
4.16%
Invesco International Dividend Achievers ETF
2.69%
Amplify International Enhanced Dividend Income ETF
2.67%
Altrius Global Dividend ETF
2.35%
SGI Enhanced Global Income ETF
2.07%
Pacer Global Cash Cows Dividend ETF
2.06%
Abacus FCF International Leaders ETF
1.9%
SP Funds S&P World (ex-US) ETF
1.78%
The Opal International Dividend Income ETF
1.74%
查看更多
VanEck Pharmaceutical ETF
占比5.37%
Cullen Enhanced Equity Income ETF
占比4.16%
Invesco International Dividend Achievers ETF
占比2.69%
Amplify International Enhanced Dividend Income ETF
占比2.67%
Altrius Global Dividend ETF
占比2.35%
SGI Enhanced Global Income ETF
占比2.07%
Pacer Global Cash Cows Dividend ETF
占比2.06%
Abacus FCF International Leaders ETF
占比1.9%
SP Funds S&P World (ex-US) ETF
占比1.78%
The Opal International Dividend Income ETF
占比1.74%
分红派息
近5年累计派现
36.74B
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
Feb 20, 2025
NVS.NB Approximate final Cash Dividend of gross USD 3.869541 going ex on Mar 12, 2025
Mar 12, 2025
May 01, 2025
Mar 12, 2025
Feb 12, 2024
NVS.NB Final Cash Dividend of gross USD 3.739544 paid on Apr 19, 2024 going ex on Mar 07, 2024
Mar 08, 2024
Apr 19, 2024
Mar 07, 2024
Feb 02, 2023
NVS.NB Final Cash Dividend of gross USD 3.498699 paid on Mar 20, 2023 going ex on Mar 09, 2023
Mar 10, 2023
Mar 20, 2023
Mar 09, 2023
Feb 04, 2022
NVS.NB Final Cash Dividend of gross USD 3.32525 paid on Mar 17, 2022 going ex on Mar 08, 2022
Mar 09, 2022
Mar 17, 2022
Mar 08, 2022
Jan 26, 2021
NVS.NB Final Cash Dividend of gross USD 3.199072 paid on Mar 15, 2021 going ex on Mar 04, 2021
Mar 05, 2021
Mar 15, 2021
Mar 04, 2021
Jan 31, 2020
NVS.NB Final Cash Dividend of gross USD 3.087366 paid on Mar 12, 2020 going ex on Mar 03, 2020
Mar 04, 2020
Mar 12, 2020
Mar 03, 2020
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据